140 related articles for article (PubMed ID: 33334587)
1. Structure-activity relationship studies of dipeptide-based hepsin inhibitors with Arg bioisosteres.
Kwon H; Ha H; Jeon H; Jang J; Son SH; Lee K; Park SK; Byun Y
Bioorg Chem; 2021 Feb; 107():104521. PubMed ID: 33334587
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of dye-conjugated hepsin inhibitors.
Kim K; Kwon H; Choi D; Lim T; Minn I; Son SH; Byun Y
Bioorg Chem; 2019 Aug; 89():102990. PubMed ID: 31136899
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology.
Damalanka VC; Han Z; Karmakar P; O'Donoghue AJ; La Greca F; Kim T; Pant SM; Helander J; Klefström J; Craik CS; Janetka JW
J Med Chem; 2019 Jan; 62(2):480-490. PubMed ID: 30571119
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design, synthesis, and biological evaluation of Leu-Arg dipeptide analogs as novel hepsin inhibitors.
Kwon H; Kim Y; Park K; Choi SA; Son SH; Byun Y
Bioorg Med Chem Lett; 2016 Jan; 26(2):310-314. PubMed ID: 26711145
[TBL] [Abstract][Full Text] [Related]
5. Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.
Franco FM; Jones DE; Harris PK; Han Z; Wildman SA; Jarvis CM; Janetka JW
Bioorg Med Chem; 2015 May; 23(10):2328-43. PubMed ID: 25882520
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances of Hepsin-Targeted Inhibitors.
Kwon H; Han J; Lee KY; Son SH; Byun Y
Curr Med Chem; 2017; 24(21):2294-2311. PubMed ID: 28245763
[TBL] [Abstract][Full Text] [Related]
7. Recent progress on inhibitors of the type II transmembrane serine proteases, hepsin, matriptase and matriptase-2.
Damalanka VC; Janetka JW
Future Med Chem; 2019 Apr; 11(7):743-769. PubMed ID: 30945556
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Design of High-Affinity and Selective Peptidomimetic Hepsin Inhibitors.
Knaff PM; Müller P; Kersten C; Wettstein L; Münch J; Landfester K; Mailänder V
Biomacromolecules; 2022 Jun; 23(6):2236-2242. PubMed ID: 35593713
[TBL] [Abstract][Full Text] [Related]
9. Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.
Goswami R; Wohlfahrt G; Törmäkangas O; Moilanen A; Lakshminarasimhan A; Nagaraj J; Arumugam KN; Mukherjee S; Chacko AR; Krishnamurthy NR; Jaleel M; Palakurthy RK; Samiulla DS; Ramachandra M
Bioorg Med Chem Lett; 2015 Nov; 25(22):5309-14. PubMed ID: 26421993
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of small-molecule inhibitors of hepsin.
Chevillet JR; Park GJ; Bedalov A; Simon JA; Vasioukhin VI
Mol Cancer Ther; 2008 Oct; 7(10):3343-51. PubMed ID: 18852137
[TBL] [Abstract][Full Text] [Related]
11. Discovery of O-(3-carbamimidoylphenyl)-l-serine amides as matriptase inhibitors using a fragment-linking approach.
Goswami R; Wohlfahrt G; Mukherjee S; Ghadiyaram C; Nagaraj J; Satyam LK; Subbarao K; Gopinath S; Krishnamurthy NR; Subramanya HS; Ramachandra M
Bioorg Med Chem Lett; 2015 Feb; 25(3):616-20. PubMed ID: 25556099
[TBL] [Abstract][Full Text] [Related]
12. Analysis of subpocket selectivity and identification of potent selective inhibitors for matriptase and matriptase-2.
Duchêne D; Colombo E; Désilets A; Boudreault PL; Leduc R; Marsault E; Najmanovich R
J Med Chem; 2014 Dec; 57(23):10198-204. PubMed ID: 25387268
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.
Subedi M; Minn I; Chen J; Kim Y; Ok K; Jung YW; Pomper MG; Byun Y
Eur J Med Chem; 2016 Aug; 118():208-218. PubMed ID: 27128184
[TBL] [Abstract][Full Text] [Related]
14. Allosteric antibody inhibition of human hepsin protease.
Koschubs T; Dengl S; Dürr H; Kaluza K; Georges G; Hartl C; Jennewein S; Lanzendörfer M; Auer J; Stern A; Huang KS; Packman K; Gubler U; Kostrewa D; Ries S; Hansen S; Kohnert U; Cramer P; Mundigl O
Biochem J; 2012 Mar; 442(3):483-94. PubMed ID: 22132769
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of prolyl oligopeptidase with a synthetic unnatural dipeptide.
Racys DT; Rea D; Fülöp V; Wills M
Bioorg Med Chem; 2010 Jul; 18(13):4775-82. PubMed ID: 20627594
[TBL] [Abstract][Full Text] [Related]
16. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
Xuan JA; Schneider D; Toy P; Lin R; Newton A; Zhu Y; Finster S; Vogel D; Mintzer B; Dinter H; Light D; Parry R; Polokoff M; Whitlow M; Wu Q; Parry G
Cancer Res; 2006 Apr; 66(7):3611-9. PubMed ID: 16585186
[TBL] [Abstract][Full Text] [Related]
17. Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase.
Steinmetzer T; Schweinitz A; Stürzebecher A; Dönnecke D; Uhland K; Schuster O; Steinmetzer P; Müller F; Friedrich R; Than ME; Bode W; Stürzebecher J
J Med Chem; 2006 Jul; 49(14):4116-26. PubMed ID: 16821772
[TBL] [Abstract][Full Text] [Related]
18. Identification of the first low-molecular-weight inhibitors of matriptase-2.
Sisay MT; Steinmetzer T; Stirnberg M; Maurer E; Hammami M; Bajorath J; Gütschow M
J Med Chem; 2010 Aug; 53(15):5523-35. PubMed ID: 20684597
[TBL] [Abstract][Full Text] [Related]
19. The serine proteinase hepsin is an activator of pro-matrix metalloproteinases: molecular mechanisms and implications for extracellular matrix turnover.
Wilkinson DJ; Desilets A; Lin H; Charlton S; Del Carmen Arques M; Falconer A; Bullock C; Hsu YC; Birchall K; Hawkins A; Thompson P; Ferrell WR; Lockhart J; Plevin R; Zhang Y; Blain E; Lin SW; Leduc R; Milner JM; Rowan AD
Sci Rep; 2017 Dec; 7(1):16693. PubMed ID: 29196708
[TBL] [Abstract][Full Text] [Related]
20. Phosphono Bisbenzguanidines as Irreversible Dipeptidomimetic Inhibitors and Activity-Based Probes of Matriptase-2.
Häußler D; Mangold M; Furtmann N; Braune A; Blaut M; Bajorath J; Stirnberg M; Gütschow M
Chemistry; 2016 Jun; 22(25):8525-35. PubMed ID: 27214780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
